Evidence map›Paper›PMID 32958242›Full record

ReviewProgress in molecular biology and translational science2020

The role of prion strain diversity in the development of successful therapeutic treatments.

Sara A M Holec, Alyssa J Block, Jason C Bartz

Open access · greenAbstract readReview
In one paragraph

Review in Progress in molecular biology and translational science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Structurally targeted mutagenesis identifies key residues supportingbioRxiv : the preprint server for biology · 2024
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sara A M HolecInstitute for Applied Life Sciences and Department of Biology, University of Massachusetts Amherst, Amherst, MA, United States; Department of Medical Microbiology and Immunology, School of Medicine, Creighton University, Omaha, NE, United States.
Alyssa J BlockDepartment of Medical Microbiology and Immunology, School of Medicine, Creighton University, Omaha, NE, United States.
Jason C BartzDepartment of Medical Microbiology and Immunology, School of Medicine, Creighton University, Omaha, NE, United States. Electronic address: jbartz@creighton.edu.
Creighton University · US

Funding

Zoonotic potential of CWD and influence of environmental contamination on prion propagationP01AI077774 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Glenn C Telling · 2008 to 2026
$36.1M
Mechanisms of prion strain dynamicsR01NS103763 · NINDS · CREIGHTON UNIVERSITY · PI BARTZ, JASON C · 2018 to 2022
$1.9M
NIAID NIH HHS P01 AI077774NINDS NIH HHS R01 NS103763
6 · The paper itself

Abstract

Prions are a self-propagating misfolded conformation of a cellular protein. Prions are found in several eukaryotic organisms with mammalian prion diseases encompassing a wide range of disorders. The first recognized prion disease, the transmissible spongiform encephalopathies (TSEs), affect several species including humans. Alzheimer's disease, synucleinopathies, and tauopathies share a similar mechanism of self-propagation of the prion form of the disease-specific protein reminiscent of the infection process of TSEs. Strain diversity in prion disease is characterized by differences in the phenotype of disease that is hypothesized to be encoded by strain-specific conformations of the prion form of the disease-specific protein. Prion therapeutics that target the prion form of the disease-specific protein can lead to the emergence of drug-resistant strains of prions, consistent with the hypothesis that prion strains exist as a dynamic mixture of a dominant strain in combination with minor substrains. To overcome this obstacle, therapies that reduce or eliminate the template of conversion are efficacious, may reverse neuropathology, and do not result in the emergence of drug resistance. Recent advancements in preclinical diagnosis of prion infection may allow for a combinational approach that treats the prion form and the precursor protein to effectively treat prion diseases.

Indexed as

AnimalsHumansPrion DiseasesPrionsPrPSc ProteinsPrionsPrPSc ProteinsAnti-prion therapyPrion diseasePrion strains

Identifiers

PMID32958242
PMCPMC8939712
OpenAlexW3082736458

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.